RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT06987513
StatusCompleted
PhasePhase 2
SponsorAltimmune, Inc.
Enrollment100 participants
DesignInterventional, Randomized, Parallel, Masking: Quadruple
ConditionsAlcohol Use Disorder (AUD)
InterventionsPemvidutide; Placebo
StartMay 15, 2025
Primary completionJul 30, 2026
Study completionJul 30, 2026
Results postedNot yet
Registry last updatedJul 31, 2026

Compounds on this site that cite this trial

What the registry says the trial is about

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms:

* Pemvidutide: 2.4 mg SC once weekly
* Placebo: Placebo SC once weekly

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Change from baseline in the average number of heavy drinking days per weekBaseline to Weeks 21-24

10 secondary outcomes also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.

Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.

Share thisFacebookXEmail